Walmart Slides Most Since 2022 on Slowing US Sales Growth
Share
Bloomberg's Poonam Goyal said Walmart's earnings miss is largely due to lagging pharmaceutical sales impacted by new federal negotiations aimed at delivering lower drug prices. Goyal said that it's an issue that both the company and investors are expecting to continue affecting sales. Goyal said that Walmart could have the opportunity to calm concerns about flagging US sales growth by focusing on bringing in customers with competitive pricing.
More from Australia
Resurgent inflation pressures test key Australian consumer shares
The digital cart rush redefining Australian retail profit pools
Trans-Tasman insurers battle contract churn while defending profit margins
Capital battles heat up as takeover offers challenge listed housing operators
The equities fueling the next infrastructure supercycle
Crypto networks collide with sanctions in a fight for financial access